Post-treatment analysis of biospecimens from patients with advanced melanoma demonstrated that dual blockade of LAG-3 and PD-1 leads to enhanced capacity for CD8+ T cell receptor signalling and cytotoxicity, despite the retention of an exhaustion profile [23]. The gene discussed is CD8A; the disease is melanoma.